CN114377031A - Composition for preventing urinary calculus of pet dogs and cats and promoting lower urinary tract repair - Google Patents
Composition for preventing urinary calculus of pet dogs and cats and promoting lower urinary tract repair Download PDFInfo
- Publication number
- CN114377031A CN114377031A CN202111625665.8A CN202111625665A CN114377031A CN 114377031 A CN114377031 A CN 114377031A CN 202111625665 A CN202111625665 A CN 202111625665A CN 114377031 A CN114377031 A CN 114377031A
- Authority
- CN
- China
- Prior art keywords
- urinary tract
- calculus
- composition
- cats
- repair
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/22—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fodder In General (AREA)
Abstract
The invention discloses a composition for preventing urinary calculus and promoting lower urinary tract repair of pet dogs and cats, belonging to the technical field of animal nutrition health care products. The raw materials of the composition comprise: stone formation inhibitors, stone lysing agents, epithelial cell stabilizing agents, epithelial tissue repair agents, and functionalizing agents; the inhibitor of stone formation is polyglutamic acid; the stone dissolving agent is organic acid; the epithelial cell stabilizer is a mixture of selenium yeast and d-alpha-tocopherol acetate or/and coenzyme Q10; the epithelial tissue repair agent is a mixture of dihydroquercetin and oligochitosan; the functionalizing agent is selected from amino acids, vitamins, taste enhancers or dietary fibers. The composition for preventing urinary calculus and promoting lower urinary tract repair of pet dogs and cats, disclosed by the invention, can be used for daily health care to prevent calculus formation, and can also be matched with a calculus removal therapy to prevent calculus from being formed again and repair damaged urinary tract epithelium after calculus is generated.
Description
Technical Field
The invention belongs to the technical field of animal nutrition health products, and particularly relates to a composition for preventing urinary calculus and promoting lower urinary tract repair of pet dogs and cats.
Background
In recent years, the economy of pets is well developed, the breeding quantity of pet dogs and cats is increased year by year, and with the increase of the day age of the dogs and cats, the health problems are gradually shown, wherein the urinary system problems, particularly urinary calculus, are more serious. The causes of calculus formation in dogs and cats are various and not easy to be summarized, but mainly include urinary tract infection, metabolic abnormality, drinking water deficiency and the like. The lower urinary tract mainly comprises a bladder and a ureter, crystal nuclei are formed in the urinary tract, and insoluble salts formed by metal elements such as calcium, magnesium and the like are the main reasons for calculus formation. After calculus is formed, damage is often caused to lower urinary tract epithelium and mucosa along with urination action, inflammation and other reactions are caused, and therefore a series of uncomfortable symptoms, serious secondary urinary tract infection and other pathological changes are brought to dogs and cats.
CN112715751A discloses a urinary tract protection feed additive for dogs and cats and a preparation method thereof, the additive comprises 10-40 parts by weight of a Chinese alpine rush extract, 20-40 parts by weight of semen plantaginis, 5-10 parts by weight of turmeric powder and 40-60 parts by weight of a dispersing agent, and the dispersing agent is wheat bran. When the additive is added at about 1%, the drinking water amount of dogs and cats can be increased remarkably, and the urine output times can be increased, so that the metabolic end products accumulated in the serum can be discharged.
CN111214538A discloses a composition for preventing and treating lower urinary tract diseases of dogs and cats, a chewable tablet thereof and a preparation method thereof, wherein the chewable tablet comprises the following components by mass: 30-40% of active ingredients; 1.8 to 2.4 percent of adhesive; 10-15% of a humectant; 5-7% of an emulsifier; 8-10% of flavoring agent; 3-4% of antioxidant; 0.5-1% of preservative; 5-7% of a disintegrating agent; 0.1-1% of lubricant; the balance being bulking agent, the active ingredients including Quercus salicina extract, shrimp and crab shell extract, cranberry extract and herba Lysimachiae Christinae extract.
CN106819506A discloses a urinary calculus preventing feed additive, which comprises the following components in percentage by weight: 20-30% of allopurinol, 25-32% of lactase, 23-34% of magnesium citrate, 0.2-4% of sodium salicylate, 0.3-0.9% of nicotinamide and 4-9% of Chinese herbal medicine juice.
The above patent applications are all mainly made of Chinese herbal medicines as main functional components, and are supplemented with dispersing agents, flavoring agents and the like, and mainly increase the drinking water and urination of pets, control the formation of uric acid and the like in terms of functions. However, in the clinical cases, the calculus in the urinary tract of dogs and cats and the injury in the lower urinary tract of dogs and cats do not occur singly, but occur gradually, so the proposal cannot solve the problem.
Disclosure of Invention
Aiming at the problems of urinary calculus and damaged urinary tract repair of pet dogs and cats, the invention aims to provide a composition for preventing the urinary tract calculus and promoting lower urinary tract repair of the pet dogs and cats.
In order to achieve the purpose, the invention adopts the following technical scheme:
a composition for preventing urinary calculus and promoting lower urinary tract repair of pet dogs and cats comprises the following raw materials in percentage by weight: 0.1-10% of calculus formation inhibitor, 1-20% of calculus dissolvent, 0.2-10% of epithelial cell stabilizer, 0.5-10% of epithelial tissue repairing agent and 50-85% of functionalizing agent, wherein the sum of the weight percentages of all the raw materials is 100%;
the inhibitor of stone formation is polyglutamic acid;
the stone dissolving agent is organic acid;
the epithelial cell stabilizer is a mixture of selenium yeast and d-alpha-tocopherol acetate or/and coenzyme Q10;
the epithelial tissue repair agent is a mixture of dihydroquercetin and oligochitosan
The functionalizing agent is selected from amino acids, vitamins, taste enhancers or dietary fibers.
At present, for the nutritional health care products for maintaining the health of the urinary tract of a pet and preventing and treating calculi, firstly, the taste regulator induces the drinking water of the pet to supplement water and increase the urine volume; secondly, Chinese herbal medicines are used for conditioning. These approaches merely solve the problems, and do not provide solutions for preventing the reformation of calculi and for the simultaneous repair of damaged urinary tract mucosa, which are generated, for the metabolism of pets. In the research process, the inventor finds that organic acid (such as citric acid, fumaric acid, malic acid, boric acid and the like) and polyglutamic acid (with the molecular weight of 10000-200000 Da) are used together, so that the formed calculus can be promoted to be dissolved, the re-formation of the calculus can be inhibited, and simultaneously, selenium yeast, d-alpha-tocopherol acetate or/and coenzyme Q10, dihydroquercetin and oligochitosan are supplemented, so that the completeness of epithelial cells of the urinary tract can be maintained, and the repair of damaged epithelial mucosa can be promoted.
The main components of the canine cat calculus comprise calcium oxalate, calcium carbonate, magnesium ammonium phosphate and the like, and organic acid (such as citric acid, fumaric acid, malic acid, boric acid and the like) can acidify urine, play a role in dissolving and softening calculus to a certain extent and inhibit the generation of calculus. Meanwhile, in the research process, the inventor finds that polyglutamic acid with the molecular weight of 20000-200000 Da can remarkably complex calcium, magnesium, zinc and the like to form a soluble complex, so that insoluble metal salt is avoided being formed, and the formed insoluble salt can be inhibited from forming insoluble salt again after being acidified and dissolved.
The inventors have found that the dissolution of calcium carbonate, calcium oxalate and the like can be accelerated and the re-formation of insoluble salts can be suppressed by using an organic acid (such as citric acid, fumaric acid, malic acid, boric acid and the like) in combination with polyglutamic acid having a molecular weight of 20000 to 200000Da in a ratio of 10:1 to 1: 2. However, when the organic acid is used alone, even if the calculus is dissolved, the insoluble salt is formed again after the pH of the system is changed.
The epithelial cell stabilizer can stabilize cell membrane, and prevent apoptosis and death. The selenium yeast and the d-alpha-tocopherol acetate or the coenzyme Q10 are used together, so that the selenium yeast and the d-alpha-tocopherol acetate or the coenzyme Q10 can effectively play a stronger antioxidation role, remove free radicals, prevent cells from being damaged, protect the health of the cells, stabilize cell membranes, reduce apoptosis and death, and maintain the integrity of epithelial mucosa of the urinary tract, and are especially important when inflammation and peroxidation damage occur.
The biggest harm of calculus and urinary crystallization before calculus formation is that the urinary epithelium is damaged to cause epithelial inflammation and secondary bacterial infection, the combination of dihydroquercetin and oligochitosan (molecular weight is 1000-10000 Da) can play a role in inhibiting inflammation, and the inventor finds that the combination of dihydroquercetin and oligochitosan (molecular weight is 1000-10000 Da) can also promote the recovery of the damaged urinary epithelium mucosa in the research process.
The functional agent can provide necessary amino acid, vitamins and the like for life activities, can improve the internal environment of the intestinal tract of the pet and help digestion, wherein the taste enhancer is derived from dried animal meat products and is used for improving the mouthfeel of the pet.
Further, the molecular weight of the polyglutamic acid is 20000-200000 Da.
Further, the organic acid is selected from one or more of citric acid, fumaric acid, malic acid or boric acid.
Further, the molecular weight of the chitosan oligosaccharide is 1000-10000 Da.
Furthermore, the composition for preventing urinary calculus and promoting lower urinary tract repair of pet dogs and cats comprises the following raw materials in percentage by weight: 0.5-10% of calculus formation inhibitor, 5-20% of calculus dissolvent, 0.5-8% of epithelial cell stabilizer, 1-10% of epithelial tissue repairing agent and 50-85% of functionalizing agent, wherein the sum of the weight percentages of all the raw materials is 100%.
The composition for preventing urinary calculus and promoting lower urinary tract repair of pet dogs and cats can be prepared into different forms of oral dosage forms according to eating habits and convenience of different animals when used on site and methods well known by technicians in the field.
The composition for preventing urinary calculus and promoting lower urinary tract repair of pet dogs and cats can be used for daily health care to prevent calculus formation, and can also be matched with a calculus removal therapy to prevent calculus from being formed again and repair damaged urinary tract epithelium after calculus is generated. The using method comprises the following steps: calculated according to the weight of the pet, 2-4 g of the oral liquid is taken every 5kg of the weight of the pet per day.
Compared with the conventional product, the composition for preventing urinary calculus and promoting lower urinary tract repair of pet dogs and cats has the following advantages and beneficial effects: (1) promoting the dissolution and elimination of the formed urinary calculus and preventing the calculus from being formed again; (2) preventing the formation of calculus; (3) repairing damaged epithelial mucosa of urinary tract.
Drawings
FIG. 1 shows a beaker A and a beaker B of test example 1 before adding sodium carbonate.
FIG. 2 shows a beaker A and a beaker B after adding sodium carbonate in test example 1.
FIG. 3 results of the beaker B in test example 1 after standing for 2 hours.
Detailed Description
The invention is described in further detail below with reference to the figures and the specific examples, which should not be construed as limiting the invention. Modifications or substitutions to methods, procedures, or conditions of the invention may be made without departing from the spirit and scope of the invention. The experimental methods and reagents of the formulations not specified in the examples are in accordance with the conventional conditions in the art.
The selenium yeast used in the following examples is a commercial feed additive, and the selenium content is greater than 2000 mg/kg; polyglutamic acid is purchased from Nanjing Xuan Kai Biotech GmbH, and has molecular weight of 20000-200000 Da and 800000-1000000 Da; the oligochitosan is purchased from Shandong Weikang biological medicine science and technology limited company, and has the molecular weight of 1000-10000 Da.
Example 1
A composition for preventing urinary calculus and promoting lower urinary tract repair of pet dogs and cats comprises the following raw materials in parts by weight: 10 percent (weight percentage, the same below), 5 percent of polyglutamic acid (molecular weight is 20000-200000 Da), 5 percent of dihydroquercetin, 2 percent of oligochitosan (molecular weight is 1000-10000 Da), 0.2 percent of yeast selenium, 3 percent of d-alpha-tocopherol acetate, and coenzyme Q102 percent of taurine, 2 percent of glutamine, 15 percent of xylo-oligosaccharide and 53.8 percent of chicken powder, and magnesium stearate accounting for 0.5 percent of the total weight of the materials is added, mixed evenly and pressed into tablets. 2-4 g of the composition is orally taken every 5kg of body weight every day.
Example 2
The other composition for preventing urinary calculus and promoting lower urinary tract repair of the pet dogs and cats comprises the following raw materials in parts by weight: 5% of citric acid (weight percentage, the same below), 5% of fumaric acid, 10% of polyglutamic acid (molecular weight 20000-200000 Da), 3% of dihydroquercetin, 1.5% of oligochitosan (molecular weight 1000-10000 Da), 0.5% of yeast selenium, 2% of d-alpha-tocopherol acetate, and coenzyme Q101 percent of taurine, 1 percent of glutamine, 5 percent of xylo-oligosaccharide and 56 percent of beef powder, and evenly mixing the components into powder. 2-4 g of the composition is orally taken every 5kg of body weight every day.
Example 3
The invention also provides a composition for preventing urinary calculus and promoting lower urinary tract repair of pet dogs and cats, which comprises the following raw materials in parts by weight: 10% of citric acid (weight percentage, the same below), 5% of fumaric acid, 5% of polyglutamic acid (molecular weight 20000-200000 Da), and two2% of hydroquercetin, 3% of oligomeric chitosan (molecular weight is 1000-10000 Da), 0.3% of yeast selenium, 5% of d-alpha-tocopherol acetate, 5% of taurine, 3% of glutamine and vitamin B20.03 percent and vitamin B60.04%, xylo-oligosaccharide 10%, chicken powder 51.63%, and wet mixing with drinking water with dry matter content of 35% to obtain semisolid paste. 2-4 g of the composition is orally taken every 5kg of body weight every day.
Example 4
The invention also provides a composition for preventing urinary calculus and promoting lower urinary tract repair of pet dogs and cats, which comprises the following raw materials in parts by weight: 5 percent (weight percentage, the same below), 5 percent of boric acid, 3 percent of polyglutamic acid (molecular weight is 20000-200000 Da), 4 percent of dihydroquercetin, 2 percent of oligomeric chitosan (molecular weight is 1000-10000 Da), 0.3 percent of yeast selenium, 4 percent of d-alpha-tocopherol acetate, and coenzyme Q101%, taurine 3%, glutamine 3%, xylo-oligosaccharide 10%, vitamin B20.05 percent of chicken powder, 59.65 percent of chicken powder and magnesium stearate accounting for 0.5 percent of the total weight of the materials are added, mixed evenly and pressed into tablets. 2-4 g of the composition is orally taken every 5kg of body weight every day.
Comparative example 1
This comparative example differs from example 2 in that: polyglutamic acid (with the molecular weight of 20000-200000 Da) is not added.
The other composition for preventing urinary calculus and promoting lower urinary tract repair of the pet dogs and cats comprises the following raw materials in parts by weight: 5 percent of citric acid (weight percentage, the same below), 5 percent of fumaric acid, 3 percent of dihydroquercetin, 1.5 percent of oligomeric chitosan (molecular weight is 1000-10000 Da), 0.5 percent of yeast selenium, 2 percent of d-alpha-tocopherol acetate and coenzyme Q101 percent of taurine, 5 percent of glutamine, 10 percent of xylo-oligosaccharide and 66 percent of beef powder, and evenly mixing the components into powder.
Comparative example 2
This comparative example differs from example 2 in that: the added polyglutamic acid has the molecular weight of 800000-1000000 Da.
The other composition for preventing urinary calculus and promoting lower urinary tract repair of the pet dogs and cats comprises the following raw materials in parts by weight: citric acid 5% (by weight, the same below), fumaric acid 5%, and polyglutamic acid(molecular weight 800000-1000000 Da) 10%, dihydroquercetin 3%, oligomeric chitosan (molecular weight 1000-10000 Da) 1.5%, yeast selenium 0.5%, d-alpha-tocopherol acetate 2%, coenzyme Q101 percent of taurine, 1 percent of glutamine, 5 percent of xylo-oligosaccharide and 56 percent of beef powder, and evenly mixing the components into powder.
Test example 1
This test example is a test for preventing calcium carbonate formation by the composition of the present invention
(I) test materials
(1) Test samples: the sample prepared in example 2 (test sample for short).
(2) Test reagents: calcium chloride and sodium carbonate, both of which are analytically pure.
(II) test method
5g of the test sample was placed in a beaker and 20mL of purified water was added and stirred for 5 minutes, and the filtrate (for easy observation) was filtered and taken for further use. 0.1g of calcium chloride is weighed into two beakers A and B respectively, 200mL of purified water is added into the beakers A and B respectively to be stirred and dissolved, then the filtrate of the test sample is added into the beaker A and stirred fully, and the beaker B is not added. Two portions of 0.1g sodium carbonate were weighed, added to the A and B beakers, respectively, and stirred for 5 minutes to observe whether white precipitate (calcium carbonate) was generated.
(III) test results
By observing the generation of the precipitates in the beakers A and B, the white precipitates are hardly generated in the beaker A (added with the test sample filtrate) after the sodium carbonate is added, and more white precipitates are generated in the beaker B, which is shown in figures 1-3.
The results show that the sample prepared in example 2 is effective in inhibiting the formation of insoluble calcium salts (calcium carbonate).
Test example 2
This test example is a test in which the composition of the present invention promotes dissolution of calcium carbonate and inhibits reformation of calcium carbonate
(I) test materials
(1) Test samples: samples prepared in example 2, comparative example 1 and comparative example 2.
(2) Test reagents: calcium chloride, sodium carbonate and sodium hydroxide, all of analytical purity.
(II) test method
2 samples of example 2, comparative example 1 and comparative example 2 (5 g each) were placed in a beaker and added to 20mL of purified water, stirred for 5 minutes, and the filtrate (for easy observation) was filtered and kept ready. 0.1g of five parts of calcium chloride are weighed and respectively added into A, B, C, D beakers and E beakers, 200mL of purified water is respectively added and stirred for dissolution, and 0.1g of five parts of sodium carbonate are weighed and respectively added into A, B, C, D beakers and E beakers and stirred for 5 minutes, so that white precipitate (calcium carbonate) is generated. Filtering and drying the precipitate in the beaker A to constant weight, and precisely weighing; adding the filtrate of the sample in the example 2 into a beaker B, fully stirring, observing the dissolution condition of the precipitate, filtering the precipitate in the beaker after 30 minutes, drying to constant weight, and precisely weighing; adding the filtrate obtained in the example 2 into a beaker C, fully stirring, dropwise adding 1mol/L sodium hydroxide solution while stirring to pH9.0, observing the precipitation condition, filtering the precipitate in the beaker after 30 minutes, drying to constant weight, and precisely weighing; adding the filtrate of the sample in the comparative example 1 into a beaker D, fully stirring, dropwise adding 1mol/L sodium hydroxide solution while stirring to pH9.0, observing the precipitation condition, filtering the precipitate in the beaker after 30 minutes, drying to constant weight, and precisely weighing; adding the filtrate of the sample in the comparative example 2 into an E beaker, fully stirring, dropwise adding 1mol/L sodium hydroxide solution to pH9.0 while stirring, observing the precipitation condition, filtering the precipitate in the beaker after 30 minutes, drying to constant weight, and precisely weighing.
(III) test results
Test results the pellet weights of the respective samples are shown in table 1.
TABLE 1 amount of precipitate obtained after different treatments
From the test results of the above examples, it can be seen that the sample prepared in example 2 is effective in promoting dissolution of insoluble calcium salts (test B) and inhibiting re-formation of insoluble calcium salts (test C) with a very significant difference in inhibiting re-formation of calcium salts as compared to the two comparative examples.
Test example 3
The test example is a test of the prevention and treatment effect of the composition on clinical urinary tract disease cases
(I) test materials
(1) Test samples: samples prepared in example 1 (group I) and example 3 (group II)
(2) Test animals: the outpatient treatment of pet hospitals confirmed 4 dogs (male 2, female 2) with urinary tract disease, and 5 cats (male 4, female 1). It is mainly manifested as frequent urination but less urine, listlessness, poor appetite, and individually painful urination.
(II) test method
Group I the tablets prepared in example 1 were used twice a day for 2 dogs and 2 cats in the test animals, 4g (8 tablets) per 5kg body weight per day, in the morning and at the evening, and continuously for 2 weeks; group II the unguents prepared in example 3 were applied to 2 dogs and 3 cats twice a day at 4g (about 8cm) per 5kg body weight in the morning and evening for 2 weeks and the therapeutic effect was judged. The patients with normal spirit, diet and urination are healed; the urination frequency is reduced, the urine volume is increased, and the mental improvement is effective; no improvement in mental, dietary, and urination was found to be ineffective.
(III) test results
The effective rate after 2 weeks of continuous feeding of the samples of this example is shown in table 2.
TABLE 2 effective rate
The test results show that the composition has a remarkable improvement effect on the urinary tract diseases of dogs and cats, and can better improve the discomfort.
The results of the above test examples show that the composition of the present invention can effectively inhibit the formation of insoluble calcium salts, and has a function of promoting dissolution of the formed insoluble calcium salts, and can inhibit the reformation of the insoluble calcium salts. The composition can effectively improve dogs and cats suffering from urinary tract symptoms and promote the recovery of inflammation, so that the composition can effectively promote the repair of damaged urinary tracts.
Claims (6)
1. A composition for preventing urinary calculus and promoting lower urinary tract repair of pet dogs and cats is characterized in that: the raw materials comprise the following components in percentage by weight: 0.1-10% of calculus formation inhibitor, 1-20% of calculus dissolvent, 0.2-10% of epithelial cell stabilizer, 0.5-10% of epithelial tissue repairing agent and 50-85% of functionalizing agent, wherein the sum of the weight percentages of all the raw materials is 100%;
the inhibitor of stone formation is polyglutamic acid;
the stone dissolving agent is organic acid;
the epithelial cell stabilizer is a mixture of selenium yeast and d-alpha-tocopherol acetate or/and coenzyme Q10;
the epithelial tissue repair agent is a mixture of dihydroquercetin and oligochitosan
The functionalizing agent is selected from amino acids, vitamins, taste enhancers or dietary fibers.
2. The composition for preventing urinary tract stones and promoting lower urinary tract repair of pet dogs and cats according to claim 1, wherein the composition comprises: the raw materials comprise the following components in percentage by weight: 0.5-10% of calculus formation inhibitor, 5-20% of calculus dissolvent, 0.5-8% of epithelial cell stabilizer, 1-10% of epithelial tissue repairing agent and 50-85% of functionalizing agent, wherein the sum of the weight percentages of all the raw materials is 100%.
3. The composition for preventing urinary tract stones and promoting lower urinary tract repair of pet dogs and cats according to claim 1 or 2, characterized in that: the molecular weight of the polyglutamic acid is 20000-200000 Da.
4. The composition for preventing urinary tract stones and promoting lower urinary tract repair of pet dogs and cats according to claim 1 or 2, characterized in that: the organic acid is selected from one or more of citric acid, fumaric acid, malic acid or boric acid.
5. The composition for preventing urinary tract stones and promoting lower urinary tract repair of pet dogs and cats according to claim 1 or 2, characterized in that: the molecular weight of the chitosan oligosaccharide is 1000-10000 Da.
6. The medicine for preventing and treating the lower urinary tract diseases of pet dogs and cats is characterized in that: the composition for preventing urinary tract stones and promoting lower urinary tract repair of pet dogs and cats comprising the composition as claimed in claim 1 or 2.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111625665.8A CN114377031B (en) | 2021-12-28 | 2021-12-28 | Composition for preventing urinary tract stones and promoting lower urinary tract repair of pet dogs and cats |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111625665.8A CN114377031B (en) | 2021-12-28 | 2021-12-28 | Composition for preventing urinary tract stones and promoting lower urinary tract repair of pet dogs and cats |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114377031A true CN114377031A (en) | 2022-04-22 |
| CN114377031B CN114377031B (en) | 2023-09-12 |
Family
ID=81198313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111625665.8A Active CN114377031B (en) | 2021-12-28 | 2021-12-28 | Composition for preventing urinary tract stones and promoting lower urinary tract repair of pet dogs and cats |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114377031B (en) |
-
2021
- 2021-12-28 CN CN202111625665.8A patent/CN114377031B/en active Active
Non-Patent Citations (4)
| Title |
|---|
| B.B. TOMAZIC等: "Influence of natural and synthetic inhibitors on the crystallization of calcium oxalate hydrates", 《WORLD JOURNAL OF UROLOGY》 * |
| G.W.DRACH等: "The Paradox of Inhibition and Enhancement of the Formation of Urinary Stones", 《UROLOGICAL RESEARCH》 * |
| MALCOLM A. KELLAND等: "Kidney Stone Prevention: Dynamic Testing of Edible Calcium Oxalate Scale Inhibitors", 《CRYSTAL GROWTH ＆ DESIGN》 * |
| 张耀铮等: "榆林地区家畜结石标本的晶体分析及溶解结石的实验研究", 《畜牧兽医杂质》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114377031B (en) | 2023-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6506413B1 (en) | Compositions for treating animal diseases and syndromes | |
| EP3058833B1 (en) | Complex carbohydrate formulation for fodder, fodder comprising same, and application | |
| CN114711336A (en) | Anti-diarrhea formulations avoiding antimicrobial resistance | |
| JP4428553B2 (en) | Prophylactic and / or therapeutic agent for domestic animals | |
| CN114377031B (en) | Composition for preventing urinary tract stones and promoting lower urinary tract repair of pet dogs and cats | |
| JP2013231073A (en) | Pathogenic attenuation via administration of equilibiotic compound | |
| JP4693777B2 (en) | Calcium deficiency preventive and / or therapeutic agent | |
| EP2627194B1 (en) | Use of benzoic acid or salt thereof to reduce urinary tract disorders in ruminants | |
| CN112891360A (en) | New application of deoxyrhaponticin | |
| JPH07118162A (en) | Oral administration composition for livestock | |
| KR20010068226A (en) | composition containing chitosan oligo saccharide and aminoethyl sulfonic acid for use as fodder and drinking water additives | |
| JP5248438B2 (en) | Ruminant milk production improver | |
| RU2308188C2 (en) | Application of feedstuff treated with "hymizyme" polyenzymatic preparation in case of intoxication with heavy metals in animals and hens | |
| JP7396603B1 (en) | licorice extract | |
| JP7396604B1 (en) | How to improve the health of mammals or livestock | |
| CN114376983B (en) | Natural extract composite granule suitable for high uric acid population | |
| WO2024075330A1 (en) | Method for improving health condition of mammal or farm animal | |
| RU2081634C1 (en) | Curative-prophylaxis agent | |
| JP2012044937A (en) | Composition for suppressing reduction in feeding amount of feed | |
| CN112106885A (en) | Calcium borogluconate solution for pets and preparation method thereof | |
| Svoboda et al. | Iron deficiency in suckling piglets: Parenteral and oral iron administration to piglets | |
| CN114916617A (en) | Cattle and sheep B-family vitamin premix and preparation method and application thereof | |
| CN115531444A (en) | Pharmaceutical composition for preventing/treating cat lithiasis and preparation method and application thereof | |
| CN113598278A (en) | Pet sterilization nutritional food | |
| JP2024053915A (en) | Mammal or livestock supplement |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |